Phase 3 Myotonic Dystrophy Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Myotonic DystrophyDM1Steinert Disease+2 more
Dyne Therapeutics150 enrolled6 locationsNCT07486934
Recruiting
Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Muscular Dystrophy, DuchenneDMDNeuromuscular Diseases (NMD)+10 more
Dyne Therapeutics90 enrolled1 locationNCT07608432
Recruiting
Phase 3
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
Myotonic Dystrophy
Lupin Ltd.176 enrolled7 locationsNCT06523400
Recruiting
Phase 3
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
MetforminMyotonic Dystrophy 1Steinert's Disease
Assistance Publique - Hôpitaux de Paris142 enrolled1 locationNCT05532813
Recruiting
Phase 2Phase 3
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Congenital Myotonic Dystrophy
AMO Pharma Limited76 enrolled14 locationsNCT05004129